AstraZeneca's Farxiga Shows 'Overwhelming Efficacy' in Phase III CKD Trial

AstraZeneca’s Farxiga could be closer to securing approval as a treatment for chronic kidney disease (CKD). This morning, the company said it halted its Phase III trial for this indication early due to “overwhelming efficacy.”